Cor Vasa 2021, 63(2):264-270 | DOI: 10.33678/cor.2021.033

2021 ACC update of the heart failure guidelines

Jindřich Špinar^a, Filip Málek^b, Lenka Špinarová^a, Jiří Vítovec^a, Miloš Táborský^c, Aleš Linhart^d

^a I. interní kardioangiologická klinika, Lékařská fakulta Masarykovy univerzity a Fakultní nemocnice u sv. Anny v Brně

^b Kardiologické oddělení, Nemocnice Na Homolce, Praha

^c I. interní klinika – kardiologická, Lékařská fakulta Univerzity Palackého v Olomouci a Fakultní nemocnice Olomouc

^d II. interní klinika kardiologie a angiologie, 1. lékařská fakulta Univerzity Karlovy a Všeobecná fakultní nemocnice v Praze

The American College of Cardiology has published an update of the heart failure guidelines treatment in the beginning of the year 2021. We bring short information about this document. It is expected that the European Society of Cardiology will publish new European guidelines this year, which will probably confi rm the increasing indication for sacubitril valsartan (ARNI) and for SGLT2 inhibitors, as a new drug class for heart failure treatment. The percutaneous access for the treatment of mitral regurgitation is also a new one. The whole document has 32 pages.

Keywords: ARNI, Guidelines, Heart failure, SGLT2 inhibitors

Received: March 4, 2021; Accepted: March 8, 2021; Published: May 1, 2021  Show citation